Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
EFFE~VESCENT COMPOSITION WITH ANALGESIC ACTIVITY
The present invention relates to a pharmaceutical composition with
S analgesic activity and, more particularly, it relates ~o a pharma-
ceutical effervescent composition containing Ibuprofen as active
in~redient and useful for the preparation of efferYescent tablets
or granulates~
Ibuprofen ~2-(4-isobutyl-phenyl)-propionic acid7 is a physically
well-tolerated drug with analgesic and antiinflammatory activity
(Merck Index, 10th Edition, No. 47973 which ;yet shows two disad-
vantages constituted by some irritability of gastric mucosa and by
a relatively slow kinetics of absorption which is the cause of- a
delay in showing the analgesic effect~
These unfavourable factors come out especial:Ly when the drug is
administered by oral route in the form of a tablet.
Besides, the administration of the drug as an aqueous suspension
is not suitable in that it has a very bitter taste and it is
irritant for the mucosa of the mouth.
In ~heory it is'possible to overcome these pro'blems by administer-
ing an aqueous solution of the drug, yet Ibuprofen has a very low
solubility in wa~er and ~he solubilization of its salts in a rea-
sonable volume of water needs long periods o time and heating,
such~operations being not compatible with the use of an analgesic
~5 carried out directly by the patient himself.
In a way simllar to that reallzed for other drugs with the same
- kind of activity, for example acetylsalicylic acid, it has been
thought then ~o prepare effervescent tablets which could ensure a
fast solubilization of the drug.
Nevertheless the usual efferrescent preparations suitable in
~d ~
: ...... , : . , .
.: . ' ., . , ,: ' . . . .
. ... . . . .. ..
- ~2763~3
pharmaceutical technology did not give the desired effect, as
Ibuprofen resul-ted still very lit~le soluble wi~h the formation of
crystals of the drug on the bottom or on the inside walls of the
glass in which the drug has been dissolved.
~e have now surprisingly found an effervescent composition which
overcomes all the above discussed unfavourable features and which
can be used for the preparation of effervescerlt tablets or granu
lates with an easy and immediate useO
The composition according to the present invention consists of
Ibuprofen 9-17% w/w
Arginine 17-33% w/w
Sodium or potassium bicarbonate 20-35~ w/w
Sodium bitartra~e 25-40% w/w
15 ~1e whole being 100%.
Preferably the weight ratio between Ibuprofen and Arginine is
about l:l.9.
The composition object of the preserlt invention is peculiar in its
con1ponents. Particularly, the most binding factor is the use of
2~ sodium bitartrate (tartaric acid monosodium sa:Lt) as an acid agent
able to develop carbon dioxide from bicarbonate.
Surprisingly, the commonly used acids for the preparation of
effervescent tablets (Pharmaceutical Dosage Forms - Tablets, vol.
1, edited by ~.A. Lieberman, L. Lachman - Marcel Dekker, Inc. -
New York and Basel) such as citric acid, tartaric acid, monosodiumcitrate, sodium citrate and others~ showed to bP unsuitable as,
already during the phase of effervescence, it was possible to
observe the formation of precipitates essentially consisting of
Ibuprofen (see example 6).
Sodium or potassium bicarbonate could be substituted by the
,
' ' ~
.
L3
corresponding carbonates or by sodium glycine-carbona~e~ but with
no prac~ical and economic advan~age
~ nstead of sodium bitartrate, potassium bitartrate as well could
S be use but the latter is difficult to be found on the market in
industrial amounts~
Arginine is another essential factor for the solubilization of
IbuprofenO
If desired it is possible to substitute a porrion of arginine (up
to 30~40~ at the most) with lysine.
Nevertheless larger amounts of lysine mak~ unacceptable the
composition from the pharmaceutical point of view since lysine
easily degrades making of a brown colour the pharmaceutical
preparation.
lS It is important to note that the use of arginine or lysine salts
of Ibuprofen ~U.SO Patent No. 4,279,926 - SPA) is not suitable in
the preparation of effervescent compositions because it does not
result in a complete solubilization of the Ibuprofen (see example
7).
~oreover, it is important to underline that, without monosodium
tartrate and bicarbonate, there is no aqueous solubilization of
the Ibuprofen-arginine mixture under conditions suitable for the
pharmaceutical applications. Likewise the monosodium tartrate-
bicarbonate system is not able to dissolve Ibuprofen in water in
the absence of arginine.
The compositions according to the present inven~ion, on the
contrary, are completely soluble in a short period of ti~e, they
show a very good tolerability on the level of both oral and
gastric mucosa and moreover they allow a faster absorption of
Ibuprofen with a consequently faster analgesic effect.
- . :, , .: .''. :
- - . :: - . . .
- , ~
~7~3
The increase of ~he absorption rate was es~imated by evalutation
of plasma concen~rations after oral administering of aqueous
solutions of effervescent tablets according to the present inven-
S tion containing 200 mg of Ibuprofen and after oral administeringof Ibuprofen commercial tablets with the same amount of active
ingredient (see example 8).
The al1alysis of plasma concentration/time curve showed a remark-
able anticipation of the peak time9 a significant decrease of lag
~ time and an increase of the mean plasma concentration (C max). The
other pharmacokinetic parameters (AUC~ distribution volume, total
clearance) are substantially the same.
The analgesic effect of the preparation ob;iect of the present
invention ends after a period of time ~rom the administration
subs~antially equal to that of Ibuproen comme~cial solid prepara-
tions. Therefore, the analgesic effect begins in advance and it
lasts for a longer period of time~
Some specific examples of the c~mposi~ions according to the
present invention are the following (percentage in weight):
(a) Ibuprofen 9.59%
Arginine 18.47~
3 33.57%
Sodium bitartrate 38.37%
(b) Ibuprofen 9.59%
~5 Arginine 12.00%
Lysine ~6.47%
3 33-57%
Sodium bitartrate 38.37%
(c) Ibuprofen 11.87~
Arginine 22.84%
. ~ ,
., ~
- ~
. .
~ 2 ~ 3
Na~003 29.67%
Sodium bitar~rate 35.62%
(d) Ibuprofen 11O87%
S Arginine 19.84%
Lysine 3O00%
KHC03 29.67~
Sodium bitartrate 35.62%
(e) IbuproYen 13.47%
Arginine 25.92%
NaHC03 26.94~
Sodium bitartrate 33.67%
(f) Ibuprofen i6.88~
Arginine 32-49%
NaHC03 - 21.09%
Sodium bitartrate 29.54%
For practical uses) the compositions object of the present inven-
tion are prepared in the form of an effervescent tablet or of an
effervescent granulate.
Preferably every single effervescent tablet contains an effective
amount of Ibuprofen that, according to the usu~l procedure, is 200
or 400 mg.
Likewise the granulate is preferably packed in bags each contain-
ing an amount of composition corresponding to 200 or 400 mg of
~5 Ibuprofen.
The preparation of the effervescent tablets or granulates needs
that additives for pharmaceutical use are added to the composi-
tion.
The choice of such additivel and their arnount may vary according
to the dosage form of the preparation (tablet or granulate) but
.
.. . . .
' . ' ' ~ ' ~ ' '' ''
. . , " " ' . ..
. . ' , . ' ' ~ '
-- 6 --
both pharmaceutical preparations have a sweetener and a flavouring
agent.
The sweetener may be a sugar (sacharose, fructose~ sorbitol,
lactose and so on), an artificial sweetener (saccharin, cycla-
matcs~ aspartame and so on) or their mixturcs.
Some pharmaceu~ically acceptable dyes may be added to both pharma-
ceutical preparations
The efferYescent tablets may also contain a binder and a lubricant
(magnesium stearate, polyethylene glycol, silica, fat~y acids,
castor oil, sodium benzoate) in order to facilitate the extruding
of the tablet from the dies.
The preparation of the effervescent tablets or granulates is
~ carried out according to usual pr~cedures.
`~ 15 In order to better illustrate the present invention without
~, limiting it, the following examples are now given.
`- Example 1
Sieved Ibuprofen (200 g) and arginine t220 g) are put into a
mixer. A hot aqueous solution of sweetener consisting of saccha-
rose (335 g), lactose (450 g) and sodium saccharin (30 g) is added
to them. The whole mixture is mixed and dried in oven.
The obtained granulate is milled by mill and then arginine ( 165
g), sodium bicarbonate (700 g), monosodium tartrate ~800 g) and
mint flavour [100 g) are added to it and mixed.
Amounts of 3 g of the obtained mixture are pressed in circular
dies with 25 mm diameter giYing effervescent tablets with the
following composition:
Ibuprofen 200 mg
Arginine 385 mg
NaHC03 700 mg
- - ~ . . ... . ...
- . ,: . .
.
. ~ , . . . .
.
3~7~3
-- 7 ~
Sodium bitartrate 800 mg
Saccharose 335 mg
Lactose 450 mg
5 Sodium saccharin30 mg
Mint flavour 100 mg
By operating according to the procedure above ~escribed, efferves-
cent tablets (3 g weight, 25 mm diameter) are prepared in which
NaHC03 is substituted by an equal amount of KH~03.
F~ample 2
The effervescent tablets of Example 1 were also prepared according
to the following procedure.
Ibuprofen (200 g) and arginine (385 g) were wet granula~ed and the
dried granulate was additioned and admixed with sodium bicarbonate
(700 g~ and sodium bitartrate (800 g)O
Saccharose (335 g), lactose (450 g~ sodium saccharin (30 g) and
mint flavour (100 g) were added to the above reported composition.
~nounts of 3 g of the obtained mixture were pressed in circular
dies with 25 mm diameter giving effervescent tablets.
20 Example 3
3 By working in a way similar to that described in example 1 effer-
vescent tablets (1.625 g weightS 18 mm diameter) with the ~ollow-
ing composition are prepared:
Ibuprofen 200 mg
25 Arginine ~ 385 mg
NaHC03 400 mg
Sodium bitartrate 500 mg
Aspartame 40 mg
Anise flavour 100 mg
Alternatively, amounts of 1.625 g of the mixture are distributed
.
. . , - - : . .
' `, "' ' ~'.' . '
: . .. : .: ~ . , ,
. .
.. :.- ~ . : ~
~7G~
-- 8 --
in payer-aluminum~polythene bags instead of being pressed.
E~ample ~
By working in a way similar to that described in example 1 effer-
vescent -tablets (3.54 g weight3 25 mm diameter) with the following
composition are prepared:
Ibuprofen 400 mg
~rginine 770 mg
NaHC03 1000 mg
10 Sodium bitartra`te 1200 mg
Aspartame 40 mg
~Sint flavour 100 mg
Cupric chlorophyll 30 mg
~xample 5
By working in a way similar to that described in example 1 effer-
vescent tablets (2.5 g weight5 22 mm diameter) with the following
composition are prepared:
Ibuprofen 400 mg
Arginine 770 mg
20 NaHC03 500 mg
Sodium bitartrate 700 mg
Aspartame 40 mg
Anise flavour . 90 mg
Al~ernàtively, amounts of 2.5 g of ~he mixture are distributed in
~S paper-aluminum-polythene bags instead of being pressed.
Example 6
.
By operating according to the procedure described in Example 1,
effervescent tablets (3 g weight, 25 mm diameter) were prepared
having the same qualitative and quantitative composition as that
of Example 1 (herein after referred as Composition 1) except for
.
~', ' ~ ' ' .
. ' . ' : : ~ . - .
'
the fact that sodium bitartrate was replaced by an identical
2mount of the following acidsO
Citric acid (Reference composition A~
Citric acid mono sodium salt (Reference composition B)
Citric acid disodium salt (Reference composition C)
Tartaric acid ~Reference composition D)
Fumaric acid (Reference composition E3
Succinic acid (Reference composition F)
lO Malic acid (Reference composition G)
Adipic acid (Reference composition H)
The tablets corresponding to Composition 1 and Reference composi-
tion A to H were added to 10Q ml of water at the temperature of
20C according to British Pharmacopeia 1980.
lS l~fter disintegregation of the effervescent tablets the presence
~` and the amount of precipitate (Ibuprofen) was evaluated.
: Composition 1 gave a solution and no precipitate was observed4
All the composition from A to H showed a risible and noticeable
amount of precipi~ate.
; '~0 The presence of the precipitate makes unacceptable the preparation both for the taste and for the local tolerability.
E~ample ?
~, By operating according to the procedure described in Example 1, aneffervescent tablet (3 g weight, 25 mm diameter) was prepared
.,
`~ ~5 having the following composition (Reference I):
2-(4-isobutyl-phenyl~~propionate of arginine( ) 369 mg
3 700 mg
Sodium bitartrate 800 mg
Saccharose 551 mg
30 Lactose 450 mg
- : , . ~ ,, : .. .
.
.
- : . . .
~7~ 3
- 10 -
Sodium saccharin 30 mg
Mint FlaYour 100 mg
(*) - salt of Ibuprofen with ~rginine corresponding ~o 200 mg of
Ibuprofen.
The reference tablet (I) was added to 100 ml of water a~ 20Co
After disintegregation of the effervescent tablet the formation of
a precipi.tate (Ibuprofen) could be observed~
ample 8
Aqueous solutions (100 ml) of the effervescent tablets described
in example 1 containing 200 mg of Ibuprofen (treatment A) and
Ibuprofen commercial tablets containing the sa~e amount of active
ingredient (treatment B), were administered with a single oral
dose to 12 subjects aged 35.8t2.03 years.
Each subject was apparently healthy, in particular as far as the
renal, hepatic and hematopoietic function are concerned.
For the experiment a "cross-over" design was adopted: each subject
recei~ed both preparations in two treatment sessions carried out 2
~ weeks apart, randomizing the order of administration.
i~ 20 During each of the two sessions, basal sample of venous blood were
drawn (in the morning) from each fasting subject, prior to oral
administration of the preparation A or B. Further YenOuS blood
samples were also collected 15, 30, 60, 90, 120, 240, 360 and 480
minutes after treatment.
The analytical determination of Ibuprofen in the blood samples was
carried out following the HPLC method hereinafter described.
Chromatographic conditions:
Apparatus: JASC0 BIP-1 with UV detector UVIDEC 100-V
~lobil phase: CH3CN:tetrabutylammonium hydroxide 0.005 ~1 (corrected
to pH 7 with H3P0~ (38:62)
~ . '
- : .. ~, . .
- - . , : .
,;. ,. ~ :- ' ' ,
Flow: 2 ml/mirl
Wavelenght: 225 mm
Internal standard: a solution in acetonitrile of ethyl p-hydroxy-
ben~oate o.oo48 M
5 ~11 of internal standard were added to 0.1 ml of blood. The whole
was mixed and 1 ml of mobil phase was added to it.
The organic phase was extracted and allowed to restO
After 30 minutes it was centrifuged at 4000 rpm and filtered
through a 0.45 ~m filter.
20 ~1 of the filtrate were injected into the chromatograph.
; Under the described operative conditions the retention times were
as follows:
Internal standard RT=4.5 minutes
Ibuprofen RT=5.5 minutes
The obtained results were reported in the following table.
TABLE 1
Mean plasma concentration of Ibuprofen after oral treatment with
solu~ion of effervescent tablets according to the present inven-
~ tion (treatment A) and after oral treatment with commercial Ibu-
profen tablets (treatment B). Administered dose 200 mg of active
ingredient.
. . _~_~_, =.=.==
_Ibuprofen ~ rat _n (~g~ml)
25 Treatment time after treatmen~ (Ininutes~
~20 240 360 480
A 29.1 22.7 16.5 13-0 10.4 4 9 2.2 1.1
~___ _3-4 12.9 16.8 15.4 13-3 5.8 3 1 1.9
.
.
- ... .. : ,
.
.
- ~ .: . . .. , :
.... . .
': . . ' ':
- 12 -
BioaYailability parameters
The following parameters were caleulated and svaluated.
- The area under the curve of Ibuprofen plasma concentration from
time "zero" to tlme 480 minutes (AUC obs=AVC ~_~ 480) expressed
as ~g x h x ml was calculated following the "trapezoidal
rule" method (Gibaldi ~1. and Perrier D.g "Pharmacokinetics",
pages 293-296~ Marcel Delcker Inc., New York 1975).
- The area under curve of Ibuprofen plasma concentration from
time "~ero" to "infinite" (AUCt t-~ ~ ) was calculated by the
following formula:
AUCo_~ 48Q + AUC480-~
where
AUC conc 480 min
(a) Ke = elimination constantO
- The mean peak expressed in minutes was obtained by averaging
the individual peak times.
- The mean plasma peak (C max) expressed as ~g/ml was calculated
~ by averaging the single peak values of the concentrations.
- Lag time (~inutes): is the delay between the drug administra-
tion and the beginning of absorption.
The values of the above specified bioavailability para~eters are
reported in the following table.
.
. . .
' ', ` .~' ' ':'; ' .',.''''; ' ~ '. ; ",'' ' :
., ~ . .
- 13 -
TABLE 2
Pharmacokinetic parameters obtained after oral treatmen~ w.ith
solution of Ibuprofen effervescent tablets (preparation A) and
wi~h Ibuprofen commercial tablets (preparation B). Administered
dose: 200 mg of active ingredient~
._ =
Analyzed parameter Preparation A Preparation 8
_ ~
AUC obs (~g x h x ml_ )3295.5 _ 3445-8
AUC tot (~g x h x ml )_ 3689.7 _ 3844.o
- Peak time (min.) 15.0 _ 6?~-5 _ __
Plasma concentration 29.1 19.4
C max (~g/ml)
. ._._. _ . . ___
1S Lag time (min.) 0.0 10.24
.
~5
3
- ,, : . :
,: ', ` ` : l
,
: ~ ., . ' . ' " '
.
